Graft-versus-host disease (GVHD) is a common and severe complication that occurs after stem cell transplantation, where the donor's immune cells attack the recipient's tissues.

Cynata Therapeutics (ASX:CYP) has had its induced pluripotent stem cell (iPSC) derived mesenchymal stem cell (MSCs) verified ...

and prospects of one of the stem cell types that can be employed to treat numerous neurological disorders—mesenchymal stem cells (MSCs). Despite the fact that several studies have already established ...

Study finds mesenchymal stem cells injected into periocular tissue effectively reduce inflammation in the eyes without ...

Researchers from Japan have found that treatment with mesenchymal stromal cells (MSCs) increased regulatory T cells while decreasing inflammatory TH1 and TH17 cells, highlighting MSCs' potential as a ...

Lung transplant recipients are highly susceptible to infection, the researchers noted, and P. aeruginosa is a leading cause ...

Injections into injured joints and tissues have exploded in the last decade. Though they all seem to work, here are some of what we don’t know. Joint injections used to be either cortisone or ...

Over 1,000 genes may serve as possible treatment targets for individuals with kidney disease, according to a new study, published in Science, from researchers at the Perelman School of Medicine at the ...

NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is pleased to announce the formation of a U.S.-based subsidiary, Exo-Top Inc. (“Exo-Top”), that is ...

What worked? What didn't? We're sizing up all the ads from the Super Bowl here, from PuppyMonkeyBaby to the Seal seal.